IMPACT THERAP-B (07630.HK): senaparib FLAMES median PFS hits 38.7 months

NewTimeSpace News: IMPACT Therapeutics, Inc (07630.HK) announced on October 23 that the latest clinical data for its pipeline drugs senaparib (IMP4297), IMP1734 (also known as EIK1003) and IMP1707 (also known as EIK1004) were presented as posters at the 2026 European Society for Medical Oncology (ESMO) Congress, held from October 23 to 27, 2026 in Madrid, Spain.

According to the announcement, updated data from the FLAMES study of senaparib showed that at a median follow-up of 48.5 months, median progression-free survival assessed by blinded independent central review was 38.7 months versus 13.6 months for placebo (HR=0.47); the figures were 49.8 months and 15.6 months for BRCA-mutated patients and 33.3 months and 12.9 months for BRCA wild-type patients, demonstrating benefit regardless of BRCA mutation status.

The announcement said that the objective response rate was 19.0% among evaluable patients receiving IMP1734 plus abiraterone for metastatic prostate cancer. In the Phase 1/2 study of IMP1707 in patients with HRR-mutated advanced solid tumours, Grade 3 or above anaemia and neutropenia each occurred in 1.5% of patients, and one breast cancer patient achieved a confirmed complete response at the 20mg dose level.